Rapport Therapeutics RAPP
NASDAQ RAPP
$26.12 +0.05 (+0.19%)
As of: Nov 10, 2026 · 12:38 PM EST

Rapport Therapeutics (RAPP) EBIT Margin (2026)

Updated

Rapport Therapeutics (RAPP) reported EBIT Margin of -121.08% for Q1 2026.

Analysis

Rapport Therapeutics (RAPP) EBIT Margin (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 52.42%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 24.35%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 36.01%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 30.89%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 32.97%
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 20.57%
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 35.79%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 41.71%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 32.98%
10 Rapport Therapeutics 1.27 Bn 876.60 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -121.08%
API Access

Rapport Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=RAPP&period=max&api_key=YOUR_API_KEY